Table 1.
Comparison between patients who received tocilizumab versus those who did not. The data are expressed as either median (interquartile range) or number (percentage). Category E was defined as pneumonia with respiratory failure while Category F was defined as pneumonia with respiratory failure and multi-organ dysfunction [2]. Chi-square test was used for categorical data while Mann Whitney U test was used for continuous data.
| Tocilizumab group | Control group | P value | |
|---|---|---|---|
| Number of patients | 70 | 91 | |
| Age | 52 (44–57) | 55 (48–65) | 0·001 |
| Male Sex | 47 (67·1) | 53 (58·2) | 0·248 |
| Diabetes | 33 (47·1) | 49 (53·8) | 0·399 |
| Hypertension | 16 (22·9) | 39 (42·9) | 0·008 |
| Any comorbidity | 43 (61·4) | 68 (74·7) | 0·071 |
| CRP | 115·5 (56–178·7) | 97 (88–104) | 0·314 |
| Respiratory Rate | 34(30–38) | 31(25–40) | 0·281 |
| Category | 0·753 | ||
| E | 62 (88·6) | 82 (90·1) | |
| F | 8 (11·4) | 9 (9·9) | |
| Noninvasive ventilation | 17 (24·3) | 1 (1·1) | 0·001 |
| Invasive ventilation | 2 (2·9) | 8 (8·8) | 0·122 |
| Days of hospitalization | 14 (9–25·5) | 6(3–14) | 0·001 |
| Days of follow up | 31 (11·75–48) | 7(3–50) | 0·072 |
| Discharged patients | 26 (37·1) | 30 (33) | |
| Ongoing hospitalization | 11 (15·7) | 0 (0) | |
| Deaths | 33 (47·1) | 61 (67) | 0·011 |